Thank you for Subscribing to Life Science Review Weekly Brief
Upon the departure of Bryan Stuart as CEO of Fulcrum, Robert Gould, Ph.D., is appointed interim CEO.
FREMONT, CA: Dedicated to providing high-quality medical care to patients with genetically defined diseases. Fulcrum product allows systematic drug discovery of genetically defined diseases. They seek to develop therapies that improve the quality of life for patients and their families by discovering and developing disease-modifying therapies.
Robert J. Gould, Ph.D., a biopharmaceutical company that focuses on improving the lives of patients with rare genetic diseases, has been appointed interim chief executive officer effective January 3, 2023. He was previously the founding chief executive officer of Fulcrum and is currently a member of the Board of Directors. The Board of Directors is appointing Dr. Gould to succeed Bryan Stuart. In order to find a permanent CEO for Fulcrum, the Board of Directors has begun a recruitment process.
On behalf of the Board, I want to thank Bryan for his contributions to Fulcrum during a transformative time in the companys trajectory, in which the company demonstrated proof of concept for FTX-6058, initiated a registrational trial in FSHD, and solidified our financial position with multiple successful financings. We are highly confident in the Fulcrum teams ability to continue advancing our mission and achieving our long-term goals while executing on Fulcrums strategic priorities, said Kate Haviland, chair of Fulcrums Board of Directors. Dr. Goulds deep leadership and industry experience, along with his history with Fulcrum, will enable a seamless transition, ensuring continuity of our leadership, mission, strategy, and culture. In addition to being a seasoned executive, Robert played a key role in setting the stage for Fulcrums ongoing achievements, leading Fulcrum through its transition to the public markets and its evolution into a clinical-stage company. Dr. Gould is ideally situated to lead Fulcrum at this pivotal time and to ensure a smooth transition to a new CEO following the completion of the search.
In the biopharmaceutical industry and in management, Robert J. Gould has more than 35 years of experience. Fulcrum Therapeutics was founded in 2016 by him, and he served as its founding president and CEO from 2016 to 2021. In the years between 2010 and 2015, he was CEO and president of Epizyme. Prior to joining the Broad Institute of Harvard and MIT in 2010, he served as its director of novel therapeutics. A former Merck vice president of licensing and external research, he spent over 20 years in leadership positions of increasing responsibility. His work at Merck led to the advancement of over 20 compounds from discovery to clinical development in multiple therapeutic areas. Johns Hopkins University postdoctoral studies in neuropharmacology preceded Dr. Gould's entry into industry. The University of Iowa awarded him a Ph.D. in biochemistry and Spring Arbor University gave him a B.S. chemistry degree.
I am deeply committed to Fulcrums mission and look forward to working with the talented executive team at Fulcrum as interim CEO as we continue to advance our two key clinical programs and execute on our corporate objectives, said Dr. Gould. 2023 will be a key year for Fulcrum, as we execute on our two clinical programs, FTX-6058 for sickle cell disease and losmapimod for facioscapulohumeral muscular dystrophy disorder.
I am proud of Fulcrums tremendous progress in the past few years. We have built an extraordinary leadership team, made significant advancements with all of our programs, and created a strong financial position, said Bryan Stuart. I look forward to Fulcrum continuing to deliver on the disease-modifying potential of these therapies that can have an important impact on patients lives.